Ocular Therapeutix, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
OCUL Nasdaq 2836 www.ocutx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Ocular Therapeutix, Inc.

1 Unprofitable Stock with Impressive Fundamentals and 2 We Find Risky - Jan 7th, 2026 9:34 pm
Is It Too Late To Consider Ocular Therapeutix (OCUL) After Recent Share Price Volatility? - Jan 7th, 2026 3:15 pm
3 Stocks Under $50 with Questionable Fundamentals - Jan 5th, 2026 9:34 pm
3 of Wall Street’s Favorite Stocks Walking a Fine Line - Jan 4th, 2026 9:36 pm
Ocular Therapeutix (NASDAQ:OCUL) Surprises With Q3 CY2025 Sales - Jan 2nd, 2026 4:07 pm
BofA Bullish on Ocular Therapeutix (OCUL) as AXPAXLI Targets Superiority Label and Faster Regulatory Path in Wet AMD - Dec 31st, 2025 9:25 am
H.C. Wainwright Lifts Ocular Therapeutix, Inc. (OCUL) Price Target Following Intravitreal Implant FDA Submission - Dec 11th, 2025 5:44 am
Ocular Therapeutix (OCUL) Hits 4-Year High on Axpaxli NDA Application - Dec 9th, 2025 12:23 pm
Ocular Therapeutix™ Announces Plans to Accelerate NDA Submission Timeline for AXPAXLI™ in Wet AMD - Dec 8th, 2025 5:00 am
Ocular Therapeutix (OCUL) Valuation After Accelerated AXPAXLI NDA Plan in Wet AMD - Dec 6th, 2025 7:06 am
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Dec 5th, 2025 5:00 am
Ocular Therapeutix™ Announces First Patient Randomized in HELIOS-3 Phase 3 Registrational Program for AXPAXLI™ in NPDR - Nov 24th, 2025 5:00 am
Wall Street Analysts Think Ocular Therapeutix (OCUL) Could Surge 82.48%: Read This Before Placing a Bet - Nov 20th, 2025 7:55 am
Ocular Therapeutix (OCUL) Soars 5% Ahead of Health Conferences - Nov 17th, 2025 10:44 pm
Will Ocular Therapeutix's (OCUL) SOL-R Enrollment Success Offset Weaker Financials in the Long Run? - Nov 14th, 2025 9:11 am
Ocular Therapeutix (OCUL): Evaluating Valuation After Recent Share Price Gains - Nov 13th, 2025 7:18 am
Ocular Therapeutix Stock Earns 81 RS Rating - Nov 12th, 2025 11:33 am
Ocular Therapeutix™ to Participate in November and December Investor Conferences - Nov 12th, 2025 5:00 am
RBC Capital Raises PT on Ocular Therapeutix (OCUL) to $24 Amid Solid Growth Trajectory - Nov 10th, 2025 6:16 pm
Analyst Estimates: Here's What Brokers Think Of Ocular Therapeutix, Inc. (NASDAQ:OCUL) After Its Third-Quarter Report - Nov 7th, 2025 4:51 am